Multicenter, randomized, 12 week, double-blind, placebo-controlled, parallel-group, Phase IIA study using F-fluorodeoxyglucose (FDG)-PET to measure the effects of rilapladib on in-vivo macrophage activity in subjects with established atherosclerosis

ID Number 08-1228-00002

Principal Investigator(s)
Michael E Farkouh

Department(s) or Division(s)

Research Entity
The Zena and Michael A. Wiener Cardiovascular Institute


This is a study in patients with atherosclerosis to assess safety, effect and PK of rilapladib vs. placebo over 12 weeks of dosing. Identifier: NCT00695305

Contact Information
Kshitij Shah
(212) 659-8847

Recruiting Patients: No